Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: PEX26 (ImmuneEditome ID:55670)

1. Gene summary of enriched editing regions for PEX26

Gene summary

Gene information	Gene symbol	PEX26
	Gene ID	55670
	GeneSynonyms	PBD7A\|PBD7B\|PEX26M1T\|Pex26pM1T
	GeneCytomap	22q11.21
	GeneType	protein-coding
	GeneDescription	peroxisome assembly protein 26\|peroxin-26\|peroxisome biogenesis disorder, complementation group 8\|peroxisome biogenesis disorder, complementation group A\|peroxisome biogenesis factor 26
	GeneModificationdate	20230329
	UniprotID	Q7Z412;A0A024R100;A0A0S2Z5M7
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr22:18088466-18090013:+	ENST00000329627.10	ENSG00000215193.11	PEX26	UTR3	AluSz,AluYf1	chr22:18088466-18090013:+.alignment
chr22:18088466-18090013:+	ENST00000610387.3	ENSG00000215193.11	PEX26	UTR3	AluSz,AluYf1	chr22:18088466-18090013:+.alignment
chr22:18091334-18094525:+	ENST00000329627.10	ENSG00000215193.11	PEX26	UTR3	AluSq2,AluJo,L1ME4a,AluY,(CCTC)n	chr22:18091334-18094525:+.alignment
chr22:18095818-18098683:+	ENST00000329627.10	ENSG00000215193.11	PEX26	UTR3	AluSg,AluSz,MIRc,THE1D,L1ME4b,AluSz6,FLAM_C,MIR,AluY	chr22:18095818-18098683:+.alignment
chr22:18100091-18100385:+	ENST00000329627.10	ENSG00000215193.11	PEX26	UTR3	AluSq2	chr22:18100091-18100385:+.alignment

Top

2. Tumor-specific enriched editing regions for PEX26

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr22:18088466-18090013:+	BRCA	EER	1.3852e-22
ENSG00000215193.11,PEX26	BRCA	EAG	7.6330e-20
ENSG00000215193.11,PEX26	COAD	EAG	5.1652e-23
chr22:18088466-18090013:+	HNSC	EER	1.1393e-08
ENSG00000215193.11,PEX26	HNSC	EAG	2.0202e-05
ENSG00000215193.11,PEX26	KIRC	EAG	1.5235e-03
ENSG00000215193.11,PEX26	PRAD	EAG	7.1049e-06
chr22:18088466-18090013:+	STAD	EER	1.6817e-03
ENSG00000215193.11,PEX26	STAD	EAG	1.0899e-02
chr22:18095818-18098683:+	THCA	EER	1.1881e-03
ENSG00000215193.11,PEX26	UCEC	EAG	4.4572e-02

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
ENSG00000215193.11,PEX26	KIRC	Path	EAG	2.2200e-02	4.9731e-03	0.1216
chr22:18091334-18094525:+	KIRP	Path	EER	3.1901e-02	1.3185e-02	0.2161
chr22:18095818-18098683:+	LUAD	Path	EER	3.6954e-02	1.2159e-02	0.1887

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr22:18088466-18090013:+	ESCA	EER	3.8599e-02	2.2430e-02	3.2762e+04
ENSG00000215193.11,PEX26	UVM	EAG	9.6261e-03	2.4407e-02	4.8983e-07

Top

3. Enriched editing regions and immune related genes for PEX26

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr22:18088466-18090013:+

BRCA

EER

ENSG00000116586,LAMTOR2

0.3801

2.6872e-34

3.6398e-52

0.4398

EIF4A3;ELAVL1;FBL;HNRNPA1;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

chr22:18088466-18090013:+

BRCA

EER

ENSG00000163463,KRTCAP2

0.3676

9.9438e-32

4.5623e-44

0.4063

BCCIP;DKC1;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_UV_RESPONSE_DN

chr22:18088466-18090013:+

BRCA

EER

ENSG00000130731,C16orf13

0.3647

2.6114e-31

7.6206e-52

0.4386

BCCIP;DKC1;EIF4A3;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

NK_cells_activated

GSVA_HALLMARK_UV_RESPONSE_DN

chr22:18088466-18090013:+

BRCA

EER

ENSG00000103363,TCEB2

0.3434

1.2074e-27

1.3517e-43

0.4042

BCCIP;DKC1;EIF4A3;ELAVL1;FBL;HNRNPA1;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

TCEB2

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr22:18088466-18090013:+

BRCA

EER

ENSG00000170906,NDUFA3

0.3438

1.6353e-27

5.0784e-51

0.4353

BCCIP;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

chr22:18088466-18090013:+

BRCA

EER

ENSG00000205155,PSENEN

0.3418

4.3826e-27

4.6392e-45

0.4106

BCCIP;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

PSENEN

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr22:18088466-18090013:+

BRCA

EER

ENSG00000131495,NDUFA2

0.3306

8.7500e-26

1.8500e-44

0.4080

BCCIP;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr22:18088466-18090013:+

BRCA

EER

ENSG00000005075,POLR2J

0.3336

9.2220e-26

5.2141e-48

0.4231

BCCIP;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_UV_RESPONSE_DN

chr22:18088466-18090013:+

BRCA

EER

ENSG00000135441,BLOC1S1

0.3218

3.9042e-24

3.9508e-49

0.4277

DKC1;EIF4A3;ELAVL1;FBL;HNRNPA1;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

BLOC1S1

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr22:18088466-18090013:+

BRCA

EER

ENSG00000166337,TAF10

0.3206

1.0144e-23

2.0147e-44

0.4078

BCCIP;EIF4A3;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

chr22:18088466-18090013:+

BRCA

EER

ENSG00000116586,LAMTOR2

0.3801

2.6872e-34

3.6398e-52

0.4398

EIF4A3;ELAVL1;FBL;HNRNPA1;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

chr22:18088466-18090013:+

BRCA

EER

ENSG00000163463,KRTCAP2

0.3676

9.9438e-32

4.5623e-44

0.4063

BCCIP;DKC1;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_UV_RESPONSE_DN

chr22:18088466-18090013:+

BRCA

EER

ENSG00000130731,C16orf13

0.3647

2.6114e-31

7.6206e-52

0.4386

BCCIP;DKC1;EIF4A3;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

NK_cells_activated

GSVA_HALLMARK_UV_RESPONSE_DN

chr22:18088466-18090013:+

BRCA

EER

ENSG00000103363,TCEB2

0.3434

1.2074e-27

1.3517e-43

0.4042

BCCIP;DKC1;EIF4A3;ELAVL1;FBL;HNRNPA1;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

TCEB2

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr22:18088466-18090013:+

BRCA

EER

ENSG00000170906,NDUFA3

0.3438

1.6353e-27

5.0784e-51

0.4353

BCCIP;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

chr22:18088466-18090013:+

BRCA

EER

ENSG00000205155,PSENEN

0.3418

4.3826e-27

4.6392e-45

0.4106

BCCIP;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

PSENEN

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr22:18088466-18090013:+

BRCA

EER

ENSG00000131495,NDUFA2

0.3306

8.7500e-26

1.8500e-44

0.4080

BCCIP;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr22:18088466-18090013:+

BRCA

EER

ENSG00000005075,POLR2J

0.3336

9.2220e-26

5.2141e-48

0.4231

BCCIP;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_UV_RESPONSE_DN

chr22:18088466-18090013:+

BRCA

EER

ENSG00000135441,BLOC1S1

0.3218

3.9042e-24

3.9508e-49

0.4277

DKC1;EIF4A3;ELAVL1;FBL;HNRNPA1;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

BLOC1S1

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr22:18088466-18090013:+

BRCA

EER

ENSG00000166337,TAF10

0.3206

1.0144e-23

2.0147e-44

0.4078

BCCIP;EIF4A3;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

chr22:18095818-18098683:+

ESCA

EER

ENSG00000128191,DGCR8

-0.4613

1.8757e-05

2.2227e-08

-0.4245

ACIN1;BUD13;CPSF6;CSTF2T;DDX54;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FUS;FXR1;FXR2;GNL3;HNRNPA2B1;HNRNPC;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;MOV10;MSI2;NOP56;NOP58;PRPF8;PTBP1;RBFOX2;RBM10;SAFB2;SF3A3;SND1;SRSF1;SRSF10;TARDBP;TRA2A;U2AF2;UPF1;YWHAG;ZNF184

DGCR8

Macrophages_M2

GSVA_HALLMARK_COMPLEMENT

More results

Top

4. Enriched editing regions and immune related splicing for PEX26

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr22:18088466-18090013:+

BRCA

EER

MEX

ENSG00000147403.12

chrX

154399486:154399594:154399802:154399945:154400474:154400626:154400701:154400811

-0.3051

1.9604e-20

7.3651e-44

-0.4054

BCCIP;DKC1;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr22:18088466-18090013:+

BRCA

EER

MEX

ENSG00000147403.12

chrX

154399486:154399594:154399802:154399945:154400563:154400626:154400701:154400811

-0.3051

1.9604e-20

7.3651e-44

-0.4054

BCCIP;DKC1;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr22:18088466-18090013:+

BRCA

EER

MEX

ENSG00000147403.12

chrX

154399486:154399594:154399802:154399945:154400497:154400626:154400701:154400811

-0.3051

1.9604e-20

7.4037e-44

-0.4054

BCCIP;DKC1;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr22:18088466-18090013:+

BRCA

EER

MEX

ENSG00000147403.12

chrX

154399486:154399594:154399802:154399917:154400563:154400626:154400701:154400917

-0.3051

1.9604e-20

7.3653e-44

-0.4054

BCCIP;DKC1;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr22:18088466-18090013:+

BRCA

EER

MEX

ENSG00000147403.12

chrX

154399486:154399594:154399802:154399925:154400474:154400626:154400701:154400917

-0.3051

1.9604e-20

7.3678e-44

-0.4054

BCCIP;DKC1;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr22:18088466-18090013:+

BRCA

EER

MEX

ENSG00000147403.12

chrX

154399486:154399594:154399802:154399925:154400563:154400626:154400701:154400917

-0.3051

1.9604e-20

7.3678e-44

-0.4054

BCCIP;DKC1;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr22:18088466-18090013:+

BRCA

EER

MEX

ENSG00000147403.12

chrX

154399486:154399594:154399802:154400358:154400474:154400626:154400701:154400913

-0.3051

1.9604e-20

7.3678e-44

-0.4054

BCCIP;DKC1;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr22:18088466-18090013:+

BRCA

EER

MEX

ENSG00000147403.12

chrX

154399486:154399594:154399802:154400358:154400563:154400626:154400701:154400913

-0.3051

1.9604e-20

7.3678e-44

-0.4054

BCCIP;DKC1;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr22:18088466-18090013:+

BRCA

EER

MEX

ENSG00000147403.12

chrX

154399486:154399594:154399802:154399917:154400497:154400626:154400701:154400917

-0.3051

1.9604e-20

7.4038e-44

-0.4054

BCCIP;DKC1;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr22:18088466-18090013:+

BRCA

EER

MEX

ENSG00000147403.12

chrX

154399486:154399594:154399802:154399925:154400497:154400626:154400701:154400917

-0.3051

1.9604e-20

7.4063e-44

-0.4054

BCCIP;DKC1;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPM;IGF2BP2;NOP56;NOP58;RBFOX2;TAF15;TARDBP;U2AF2

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

More results

Top

5. Enriched editing regions and immune infiltration for PEX26

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
ENSG00000215193.11,PEX26	ACC	EAG	NK_cells_activated	7.2959e-03	0.3095
chr22:18091334-18094525:+	BLCA	EER	T_cells_CD4_memory_resting	4.8753e-02	-0.2007
chr22:18095818-18098683:+	BLCA	EER	Macrophages_M1	1.0859e-02	0.2088
ENSG00000215193.11,PEX26	BLCA	EAG	Dendritic_cells_activated	4.2111e-03	-0.1419
chr22:18088466-18090013:+	BRCA	EER	NK_cells_activated	5.7107e-11	0.1979
chr22:18095818-18098683:+	BRCA	EER	Mast_cells_resting	2.6788e-02	-0.1027
ENSG00000215193.11,PEX26	BRCA	EAG	NK_cells_activated	3.1795e-08	0.1675
chr22:18088466-18090013:+	CESC	EER	T_cells_follicular_helper	2.3791e-03	0.1754
ENSG00000215193.11,PEX26	CESC	EAG	T_cells_follicular_helper	1.0058e-02	0.1474
chr22:18095818-18098683:+	CHOL	EER	T_cells_CD4_memory_activated	1.8929e-02	0.4191
ENSG00000215193.11,PEX26	CHOL	EAG	B_cells_naive	3.4737e-02	-0.3580
ENSG00000215193.11,PEX26	COAD	EAG	NK_cells_activated	1.0802e-04	0.2326
chr22:18088466-18090013:+	DLBC	EER	Macrophages_M2	1.4244e-03	0.4566
ENSG00000215193.11,PEX26	DLBC	EAG	Macrophages_M2	1.4714e-03	0.4508
chr22:18088466-18090013:+	ESCA	EER	T_cells_CD8	6.5526e-04	0.2658
chr22:18091334-18094525:+	ESCA	EER	T_cells_CD8	1.2865e-03	0.2563
chr22:18095818-18098683:+	ESCA	EER	T_cells_CD4_memory_resting	3.2172e-02	-0.1695
ENSG00000215193.11,PEX26	ESCA	EAG	T_cells_CD8	8.2746e-05	0.3052
chr22:18091334-18094525:+	GBM	EER	T_cells_CD8	1.1401e-02	0.2732
ENSG00000215193.11,PEX26	GBM	EAG	Plasma_cells	1.2799e-02	0.1940
chr22:18088466-18090013:+	HNSC	EER	T_cells_CD8	2.3376e-05	0.1893
chr22:18091334-18094525:+	HNSC	EER	B_cells_naive	7.9728e-03	-0.2005
ENSG00000215193.11,PEX26	HNSC	EAG	T_cells_CD8	1.9783e-05	0.1903
chr22:18088466-18090013:+	KICH	EER	T_cells_regulatory_(Tregs)	1.0835e-02	-0.3141
chr22:18091334-18094525:+	KICH	EER	Macrophages_M2	2.5242e-03	0.4820
ENSG00000215193.11,PEX26	KICH	EAG	T_cells_regulatory_(Tregs)	2.9479e-02	-0.2702
chr22:18091334-18094525:+	KIRC	EER	Plasma_cells	4.9363e-03	0.1938
chr22:18095818-18098683:+	KIRC	EER	Macrophages_M2	7.6047e-04	-0.2508
ENSG00000215193.11,PEX26	KIRC	EAG	Mast_cells_resting	3.5757e-03	-0.1481
ENSG00000215193.11,PEX26	KIRP	EAG	B_cells_memory	3.8805e-02	0.1220
chr22:18095818-18098683:+	LAML	EER	B_cells_memory	2.7916e-02	-0.1936
ENSG00000215193.11,PEX26	LAML	EAG	Neutrophils	7.3684e-03	0.2180
chr22:18095818-18098683:+	LGG	EER	T_cells_CD8	3.4925e-02	-0.1180
ENSG00000215193.11,PEX26	LGG	EAG	Macrophages_M2	2.1940e-03	0.1329
chr22:18088466-18090013:+	LIHC	EER	T_cells_CD4_memory_activated	2.3420e-02	0.1213
chr22:18095818-18098683:+	LIHC	EER	NK_cells_activated	4.1152e-02	0.2207
ENSG00000215193.11,PEX26	LIHC	EAG	T_cells_CD4_memory_activated	2.7712e-02	0.1160
chr22:18088466-18090013:+	LUAD	EER	T_cells_regulatory_(Tregs)	6.2161e-04	0.1516
ENSG00000215193.11,PEX26	LUAD	EAG	Eosinophils	5.5304e-04	0.1526
chr22:18091334-18094525:+	LUSC	EER	NK_cells_resting	1.6094e-02	-0.1582
chr22:18095818-18098683:+	LUSC	EER	T_cells_CD4_memory_activated	6.7874e-03	0.1644
ENSG00000215193.11,PEX26	LUSC	EAG	T_cells_CD8	1.7203e-05	0.1915
ENSG00000215193.11,PEX26	MESO	EAG	T_cells_gamma_delta	2.9788e-02	0.2416
chr22:18088466-18090013:+	OV	EER	T_cells_CD8	4.7980e-05	0.2364
chr22:18091334-18094525:+	OV	EER	Eosinophils	4.1071e-02	0.1382
chr22:18095818-18098683:+	OV	EER	Neutrophils	4.3710e-02	0.1340
ENSG00000215193.11,PEX26	OV	EAG	T_cells_CD8	3.4559e-05	0.2402
ENSG00000215193.11,PEX26	PAAD	EAG	T_cells_follicular_helper	4.1815e-03	0.2137
chr22:18095818-18098683:+	PCPG	EER	Mast_cells_resting	4.9346e-02	-0.2055
ENSG00000215193.11,PEX26	PCPG	EAG	Plasma_cells	1.2625e-02	0.1846
ENSG00000215193.11,PEX26	PRAD	EAG	T_cells_regulatory_(Tregs)	3.4486e-06	0.2061
chr22:18095818-18098683:+	SARC	EER	Macrophages_M1	4.9593e-02	0.2137
ENSG00000215193.11,PEX26	SARC	EAG	T_cells_gamma_delta	5.3017e-05	0.2503
chr22:18091334-18094525:+	SKCM	EER	Monocytes	3.2002e-03	0.1711
chr22:18095818-18098683:+	SKCM	EER	Macrophages_M0	4.6085e-03	-0.1827
ENSG00000215193.11,PEX26	SKCM	EAG	T_cells_CD8	7.6510e-06	0.2048
chr22:18088466-18090013:+	STAD	EER	T_cells_CD4_memory_resting	4.1780e-04	-0.1835
chr22:18095818-18098683:+	STAD	EER	T_cells_CD8	1.1185e-04	0.2101
ENSG00000215193.11,PEX26	STAD	EAG	T_cells_CD4_memory_activated	8.7157e-04	0.1730
chr22:18095818-18098683:+	TGCT	EER	Macrophages_M2	4.1627e-02	-0.3050
ENSG00000215193.11,PEX26	TGCT	EAG	Macrophages_M2	3.8142e-03	-0.2318
chr22:18091334-18094525:+	THCA	EER	Monocytes	2.7820e-02	-0.1288
ENSG00000215193.11,PEX26	THCA	EAG	Plasma_cells	2.1376e-03	0.1365
chr22:18095818-18098683:+	THYM	EER	T_cells_gamma_delta	1.5346e-02	0.2908
ENSG00000215193.11,PEX26	THYM	EAG	T_cells_gamma_delta	7.1000e-03	0.2466
chr22:18091334-18094525:+	UCEC	EER	Eosinophils	2.2114e-02	-0.3332
chr22:18095818-18098683:+	UCEC	EER	Dendritic_cells_activated	9.7056e-03	0.3901
ENSG00000215193.11,PEX26	UCEC	EAG	B_cells_naive	3.3093e-03	-0.2215
ENSG00000215193.11,PEX26	UCS	EAG	Eosinophils	7.9603e-08	0.6452
ENSG00000215193.11,PEX26	UVM	EAG	T_cells_CD4_memory_activated	1.2389e-02	0.2784

Top

6. Enriched editing regions and immune gene sets for PEX26

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events	cancer	Type	E2M_P	Boxplot	CorP	CorR	CorrelationPlot
chr22:18088466-18090013:+	BRCA	EER	1.9847e-04		4.1022e-05	-0.1246
ENSG00000215193.11,PEX26	BRCA	EAG	3.2948e-04		1.7420e-03	-0.0953

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000215193.11,PEX26	ACC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.3889e-05	-0.4818
chr22:18095818-18098683:+	BLCA	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	1.8574e-03	0.2538
chr22:18091334-18094525:+	BLCA	GSVA_HALLMARK_TGF_BETA_SIGNALING	EER	2.6012e-02	-0.2260
ENSG00000215193.11,PEX26	BLCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	9.3199e-07	0.2409
chr22:18095818-18098683:+	BRCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	5.3363e-06	0.2093
chr22:18091334-18094525:+	BRCA	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	4.5458e-03	0.1273
ENSG00000215193.11,PEX26	BRCA	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	7.4080e-22	0.2868
chr22:18088466-18090013:+	BRCA	GSVA_HALLMARK_UV_RESPONSE_DN	EER	1.8336e-24	-0.3040
chr22:18088466-18090013:+	CESC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	2.0778e-07	-0.2953
ENSG00000215193.11,PEX26	CESC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.1690e-04	-0.2192
chr22:18095818-18098683:+	CESC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	3.0180e-03	0.3060
chr22:18095818-18098683:+	CHOL	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	1.9363e-02	-0.4178
chr22:18095818-18098683:+	COAD	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	6.1294e-03	0.2750
ENSG00000215193.11,PEX26	COAD	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	2.4196e-04	-0.2208
chr22:18088466-18090013:+	DLBC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	4.5851e-03	-0.4107
ENSG00000215193.11,PEX26	DLBC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	1.8308e-03	-0.4428
chr22:18091334-18094525:+	ESCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	2.9515e-03	-0.2373
chr22:18095818-18098683:+	ESCA	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EER	1.6327e-02	0.1896
ENSG00000215193.11,PEX26	ESCA	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	3.5367e-03	-0.2286
chr22:18088466-18090013:+	ESCA	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	2.6183e-04	-0.2840
chr22:18091334-18094525:+	GBM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.0435e-02	-0.2764
ENSG00000215193.11,PEX26	GBM	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	7.9904e-04	-0.2593
chr22:18095818-18098683:+	HNSC	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	2.0809e-02	0.2144
chr22:18091334-18094525:+	HNSC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	4.9521e-02	-0.1491
ENSG00000215193.11,PEX26	HNSC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	7.5017e-18	-0.3733
chr22:18088466-18090013:+	HNSC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	4.0588e-17	-0.3665
chr22:18088466-18090013:+	KICH	GSVA_HALLMARK_ANDROGEN_RESPONSE	EER	3.0917e-04	-0.4335
ENSG00000215193.11,PEX26	KICH	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	9.6359e-04	-0.4000
chr22:18091334-18094525:+	KICH	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	7.7640e-03	-0.4309
ENSG00000215193.11,PEX26	KIRC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	5.5955e-05	-0.2038
chr22:18095818-18098683:+	KIRC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	3.2038e-05	0.3072
ENSG00000215193.11,PEX26	KIRP	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	3.3956e-13	-0.4121
chr22:18095818-18098683:+	KIRP	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	1.3392e-02	0.2071
chr22:18091334-18094525:+	KIRP	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	1.1361e-02	-0.2111
chr22:18095818-18098683:+	LAML	GSVA_HALLMARK_PEROXISOME	EER	8.1847e-03	-0.2319
ENSG00000215193.11,PEX26	LAML	GSVA_HALLMARK_PEROXISOME	EAG	1.2424e-03	-0.2612
ENSG00000215193.11,PEX26	LGG	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	1.6381e-10	-0.2732
chr22:18095818-18098683:+	LGG	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	2.4309e-02	0.1259
ENSG00000215193.11,PEX26	LIHC	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	1.2808e-09	-0.3129
chr22:18088466-18090013:+	LIHC	GSVA_HALLMARK_UV_RESPONSE_DN	EER	5.1874e-11	-0.3420
chr22:18091334-18094525:+	LIHC	GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING	EER	5.0134e-03	0.2785
ENSG00000215193.11,PEX26	LUAD	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	2.4240e-06	0.2072
chr22:18095818-18098683:+	LUAD	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	2.5440e-03	0.2287
chr22:18088466-18090013:+	LUAD	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	1.1252e-07	0.2332
chr22:18091334-18094525:+	LUSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.2819e-02	0.1635
chr22:18095818-18098683:+	LUSC	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	7.9917e-04	0.2029
ENSG00000215193.11,PEX26	LUSC	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	5.3255e-04	-0.1548
ENSG00000215193.11,PEX26	MESO	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	3.7726e-02	0.2313
chr22:18095818-18098683:+	OV	GSVA_HALLMARK_APOPTOSIS	EER	2.4170e-02	0.1496
chr22:18091334-18094525:+	OV	GSVA_HALLMARK_SPERMATOGENESIS	EER	2.0913e-02	0.1560
chr22:18088466-18090013:+	OV	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	5.5746e-15	-0.4374
ENSG00000215193.11,PEX26	OV	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	1.6170e-11	0.3815
ENSG00000215193.11,PEX26	PAAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	2.0563e-04	-0.2748
chr22:18095818-18098683:+	PCPG	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	1.7103e-07	0.5130
ENSG00000215193.11,PEX26	PCPG	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.2037e-06	-0.3508
ENSG00000215193.11,PEX26	PRAD	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	2.3939e-11	-0.2932
ENSG00000215193.11,PEX26	READ	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	4.3287e-03	-0.2902
ENSG00000215193.11,PEX26	SARC	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EAG	5.0666e-05	0.2509
chr22:18095818-18098683:+	SARC	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	5.8343e-03	-0.2967
chr22:18095818-18098683:+	SKCM	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	2.1172e-03	0.1979
ENSG00000215193.11,PEX26	SKCM	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	1.6882e-12	-0.3179
chr22:18091334-18094525:+	STAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	1.3692e-02	-0.1432
chr22:18088466-18090013:+	STAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	3.3083e-04	0.1866
chr22:18095818-18098683:+	STAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	4.8796e-05	0.2206
ENSG00000215193.11,PEX26	STAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	2.3213e-04	0.1910
chr22:18095818-18098683:+	TGCT	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.0340e-02	0.3786
ENSG00000215193.11,PEX26	TGCT	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	4.0504e-08	-0.4246
chr22:18095818-18098683:+	THCA	GSVA_HALLMARK_APOPTOSIS	EER	1.7411e-04	0.2381
ENSG00000215193.11,PEX26	THCA	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	5.4201e-15	-0.3387
chr22:18091334-18094525:+	THCA	GSVA_HALLMARK_MYOGENESIS	EER	2.5246e-03	0.1761
ENSG00000215193.11,PEX26	THYM	GSVA_HALLMARK_P53_PATHWAY	EAG	8.3169e-05	0.3542
chr22:18095818-18098683:+	THYM	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	8.0183e-03	0.3167
chr22:18091334-18094525:+	UCEC	GSVA_HALLMARK_UV_RESPONSE_DN	EER	2.2129e-04	-0.5137
chr22:18095818-18098683:+	UCEC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	6.4663e-03	0.4090
ENSG00000215193.11,PEX26	UCEC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.3642e-05	-0.3232
ENSG00000215193.11,PEX26	UVM	GSVA_HALLMARK_COAGULATION	EAG	1.8809e-03	0.3424

Top

7. Enriched editing regions and drugs for PEX26

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000215193.11,PEX26	ACC	LFM.A13	EAG	3.2153e-04	-0.4069
chr22:18095818-18098683:+	BLCA	CMK	EER	2.8404e-05	-0.3368
chr22:18091334-18094525:+	BLCA	AZD6482	EER	6.5519e-05	0.3939
ENSG00000215193.11,PEX26	BLCA	CCT007093	EAG	1.8899e-06	0.2342
chr22:18088466-18090013:+	BRCA	AZD6482	EER	6.1509e-17	0.2514
ENSG00000215193.11,PEX26	BRCA	AZD6482	EAG	1.3125e-12	0.2141
chr22:18091334-18094525:+	BRCA	DMOG	EER	9.1034e-04	0.1486
chr22:18095818-18098683:+	BRCA	ABT.263	EER	1.0622e-03	0.1517
chr22:18088466-18090013:+	CESC	AZD6482	EER	1.3541e-06	0.2756
chr22:18095818-18098683:+	CESC	GDC.0449	EER	1.9934e-02	-0.2423
ENSG00000215193.11,PEX26	CESC	BMS.536924	EAG	8.7454e-06	-0.2527
ENSG00000215193.11,PEX26	CHOL	AKT.inhibitor.VIII	EAG	2.8454e-02	-0.3705
chr22:18095818-18098683:+	CHOL	AG.014699	EER	2.6243e-02	-0.3989
chr22:18095818-18098683:+	COAD	CMK	EER	1.1194e-02	0.2552
ENSG00000215193.11,PEX26	COAD	Cisplatin	EAG	4.7427e-03	-0.1708
ENSG00000215193.11,PEX26	DLBC	ATRA	EAG	4.3006e-03	0.4091
chr22:18088466-18090013:+	DLBC	AICAR	EER	1.9828e-03	0.4442
chr22:18088466-18090013:+	ESCA	AZD.2281	EER	3.5396e-03	-0.2293
ENSG00000215193.11,PEX26	ESCA	AZD.2281	EAG	3.5805e-04	-0.2787
chr22:18091334-18094525:+	ESCA	GDC.0449	EER	9.7587e-04	-0.2623
chr22:18095818-18098683:+	ESCA	AZ628	EER	2.2776e-05	-0.3281
ENSG00000215193.11,PEX26	GBM	BIBW2992	EAG	3.1501e-04	-0.2779
chr22:18091334-18094525:+	GBM	CCT018159	EER	1.8473e-02	0.2551
ENSG00000215193.11,PEX26	HNSC	BMS.536924	EAG	4.0451e-22	-0.4158
chr22:18091334-18094525:+	HNSC	ABT.263	EER	2.7702e-02	0.1674
chr22:18088466-18090013:+	HNSC	BMS.536924	EER	7.7686e-23	-0.4231
chr22:18088466-18090013:+	KICH	AZD.2281	EER	1.5328e-04	-0.4526
ENSG00000215193.11,PEX26	KICH	ABT.263	EAG	6.6756e-03	0.3332
chr22:18091334-18094525:+	KICH	FH535	EER	5.0090e-03	0.4517
chr22:18091334-18094525:+	KIRC	CEP.701	EER	3.5324e-04	-0.2448
ENSG00000215193.11,PEX26	KIRC	AZD6244	EAG	1.6905e-06	-0.2412
chr22:18095818-18098683:+	KIRC	Cisplatin	EER	7.9314e-04	-0.2500
ENSG00000215193.11,PEX26	KIRP	AZD6482	EAG	4.8246e-12	0.3931
chr22:18095818-18098683:+	KIRP	A.770041	EER	1.7389e-02	-0.1993
chr22:18091334-18094525:+	KIRP	AS601245	EER	8.9913e-03	0.2177
chr22:18095818-18098683:+	LAML	Embelin	EER	7.4146e-03	0.2347
ENSG00000215193.11,PEX26	LAML	FTI.277	EAG	4.3655e-03	0.2315
ENSG00000215193.11,PEX26	LGG	GNF.2	EAG	4.1411e-10	-0.2673
chr22:18095818-18098683:+	LGG	BI.2536	EER	1.0924e-02	0.1421
chr22:18088466-18090013:+	LIHC	BAY.61.3606	EER	3.4209e-07	0.2688
chr22:18091334-18094525:+	LIHC	CGP.60474	EER	6.5875e-03	-0.2700
chr22:18095818-18098683:+	LIHC	ABT.263	EER	2.6931e-02	0.2386
ENSG00000215193.11,PEX26	LIHC	Imatinib	EAG	6.4485e-06	0.2352
chr22:18095818-18098683:+	LUAD	Gemcitabine	EER	2.2497e-02	-0.1739
chr22:18088466-18090013:+	LUAD	BMS.536924	EER	1.1757e-06	-0.2149
ENSG00000215193.11,PEX26	LUAD	BMS.536924	EAG	1.3437e-05	-0.1924
chr22:18095818-18098683:+	LUSC	CGP.60474	EER	6.7950e-04	-0.2055
ENSG00000215193.11,PEX26	LUSC	AP.24534	EAG	2.1258e-06	0.2108
chr22:18091334-18094525:+	LUSC	KU.55933	EER	1.5152e-02	-0.1596
ENSG00000215193.11,PEX26	MESO	GDC0941	EAG	4.7666e-02	-0.2208
chr22:18088466-18090013:+	OV	Embelin	EER	2.8225e-18	0.4820
ENSG00000215193.11,PEX26	OV	Bexarotene	EAG	1.4551e-14	0.4306
chr22:18091334-18094525:+	OV	DMOG	EER	8.2077e-03	0.1782
chr22:18095818-18098683:+	OV	ABT.263	EER	1.1445e-02	0.1676
ENSG00000215193.11,PEX26	PAAD	AKT.inhibitor.VIII	EAG	1.8902e-02	0.1794
ENSG00000215193.11,PEX26	PCPG	BI.D1870	EAG	5.6016e-03	0.2046
chr22:18095818-18098683:+	PCPG	AMG.706	EER	3.5282e-05	0.4171
ENSG00000215193.11,PEX26	PRAD	GNF.2	EAG	1.0059e-14	-0.3377
ENSG00000215193.11,PEX26	READ	Lapatinib	EAG	1.0885e-02	0.2602
ENSG00000215193.11,PEX26	SARC	GDC.0449	EAG	1.0342e-07	-0.3257
chr22:18095818-18098683:+	SARC	CGP.082996	EER	5.5112e-03	-0.2986
ENSG00000215193.11,PEX26	SKCM	Embelin	EAG	2.1321e-08	0.2547
chr22:18095818-18098683:+	SKCM	GDC.0449	EER	3.2245e-03	-0.1898
chr22:18091334-18094525:+	SKCM	BI.D1870	EER	1.3086e-02	0.1443
chr22:18088466-18090013:+	STAD	Cisplatin	EER	4.8012e-07	-0.2595
chr22:18091334-18094525:+	STAD	BMS.536924	EER	1.3525e-04	-0.2200
chr22:18095818-18098683:+	STAD	BMS.536924	EER	2.3739e-03	-0.1660
ENSG00000215193.11,PEX26	STAD	Cisplatin	EAG	1.5366e-05	-0.2236
chr22:18095818-18098683:+	TGCT	Cisplatin	EER	1.9857e-02	-0.3461
ENSG00000215193.11,PEX26	TGCT	Gefitinib	EAG	8.1909e-07	-0.3850
chr22:18095818-18098683:+	THCA	Cisplatin	EER	2.9901e-05	-0.2638
ENSG00000215193.11,PEX26	THCA	Embelin	EAG	1.8702e-17	0.3664
chr22:18091334-18094525:+	THCA	AZ628	EER	1.0806e-04	-0.2246
ENSG00000215193.11,PEX26	THYM	Embelin	EAG	8.2820e-04	0.3037
ENSG00000215193.11,PEX26	UCEC	Embelin	EAG	2.9521e-06	0.3458
chr22:18091334-18094525:+	UCEC	AZD6244	EER	5.2689e-04	-0.4912
ENSG00000215193.11,PEX26	UCS	JW.7.52.1	EAG	1.0908e-02	-0.3377
ENSG00000215193.11,PEX26	UVM	GSK269962A	EAG	8.0913e-04	-0.3671

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType